<DOC>
	<DOCNO>NCT01649765</DOCNO>
	<brief_summary>This multi-center study evaluate safety , pharmacokinetics , efficacy belimumab intravenous ( IV ) pediatric patient 5 17 year age active systemic lupus erythematosus</brief_summary>
	<brief_title>Pediatric Lupus Trial Belimumab Plus Background Standard Therapy</brief_title>
	<detailed_description>This multi-center study evaluate safety , pharmacokinetics , efficacy belimumab intravenous ( IV ) pediatric patient 5 17 year age active systemic lupus erythematosus ( SELENA SLEDAI score ≥ 6 ) . The study consist three phase : 52-week randomized , placebo-controlled , double-blind phase ; long term open label continuation phase ; long term safety follow phase . The long term open label continuation safety follow period continue least 5 year possibly 10 year subject 's initial treatment belimumab . Enrolment stagger age cohort allow safety PK interim analysis . Subjects randomize belimumab 10mg/kg placebo IV monthly dose continue receive background standard therapy throughout study . An independent data monitoring committee ( IDMC ) monitor study progress .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>5 year 17 year age enrollment Have clinical diagnosis SLE accord American College Rheumatology ( ACR ) classification criterion . Have active SLE disease ( SELENA SLEDAI score ≥ 6 ) . Have positive antinuclear antibody ( ANA ) test result . Are stable SLE treatment regimen fix dose period least 30 day prior Day 0 . Females childbearing age willing use appropriate contraception Subject age appropriate assent parent legal guardian inform consent participate Pregnant nursing . Have receive treatment belimumab ( BENLYSTA® ) time . ( BENLYSTA® register trademark GSK group company . ) Treatment B cell target therapy ( example , rituximab ) investigational biological agent past year . Have receive antiTNF therapy ; Interleukin1 receptor antagonist ; IVIG ; plasmapheresis within 90 day Day 0 . Have receive high dose prednisone equivalent ( &gt; 1.5mg/kg/day ) within 60 day baseline . Have receive intravenous ( IV ) cyclophosphamide within 60 day Day 0 . Have receive new immunosuppressive/immunomodulatory agent , antimalarial agent within 60 day baseline . Have severe lupus kidney disease . Have active central nervous system ( CNS ) lupus . Have major organ transplant . Have significant unstable uncontrolled acute chronic disease condition due SLE . Have plan surgical procedure . History malignant neoplasm within last 5 year . Have require management acute chronic infection past 60 day . Have current drug alcohol abuse dependence . Have historically positive test , test positive screening HIV , Hepatitis B , Hepatitis C. Have IgA deficiency . Have severe laboratory abnormality . Have anaphylactic reaction Xray contrast agent biologic agent . Suicidal behavior ideation . Children Care ( CiC ) : child place control protection agency , organisation , institution entity court , government government body , act accordance power confer law regulation .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SLE Flare Index</keyword>
	<keyword>SRI</keyword>
	<keyword>belimumab</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>B lymphocyte</keyword>
	<keyword>BLyS</keyword>
	<keyword>SELENA SLEDAI</keyword>
	<keyword>BILAG</keyword>
	<keyword>Lupus</keyword>
	<keyword>Systemic Lupus Erythematosus ( SLE )</keyword>
	<keyword>PGA</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>placebo</keyword>
	<keyword>PRINTO</keyword>
</DOC>